Background: Renal metastases from non-small cell lung cancer (NSCLC) are rare, treatment guidelines for renal metastases from NSCLC are unclear, mostly based on clinical case reports. Data on the effectiveness of osimertinib in the group of patients with renal metastatic NSCLC who have epidermal growth factor receptor (EGFR) mutations del19 or L858R is still incomplete. Purpose: In this study, we report a case of the bilateral renal metastatic NSCLC who was treated by the first-line TKIs with osimertinib. Results: This patient had a prolonged response lasting 9 months with third-generation TKI. During treatment, the patient achieved a clinical response and well-tolerated treatment. Conclusion: Renal metastatic NSCLC with TKI-sensitive EGFR mutations revealed a good response to osimertinib.
Cite this paper
Do, T. A. , Nguyen, V. T. and Tran, H. K. (2025). Osimertinib Applied in Renal Metastatic Non-Small Cell Lung Cancer with Sensitive EGFR Mutation: Good Response of a Vietnamese Woman. Open Access Library Journal, 12, e1403. doi: http://dx.doi.org/10.4236/oalib.1111403.
Siegel, R.L., Miller, K.D. and Jemal, A. (2020) Cancer Statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 7-30. https://doi.org/10.3322/caac.21590
Lian, H., Pan, X., Hong, B., Min, J. and Huang, F. (2023) Metastases to the Kidney from Pri-mary Lung Cancer: Clinicopathological Analysis of Six Cases in a Single Center. Di-agnostic Pathology, 18, Article No. 60. https://doi.org/10.1186/s13000-023-01344-6
Stoykov, B., Genov, P., Kirilov, I., Yanev, K., Kolev, N. and Dunev, V. (2021) A Rare Case of Isolated Lung Metastasis in the Kidney. Urology Case Reports, 37, Article 101616. https://doi.org/10.1016/j.eucr.2021.101616
Tomita, M., Ayabe, T., Chosa, E. and Nakamura, K. (2015) Isolated Renal Metastasis from Non-Small-Cell Lung Cancer: Report of 2 Cases. Case Reports in Surgery, 2015, Article ID: 357481. https://doi.org/10.1155/2015/357481
Wang, J., Wang, L., Long, L., Tao, Q., Xu, F. and Luo, F. (2019) Solitary Renal Metastasis from Squamous Cell Carcinoma of the Lung. Medicine, 98, e14310. https://doi.org/10.1097/md.0000000000014310
Do, K.H., Le, D.T., Van Nguyen, T., Do, T.A. and Van Nguyen, C. (2023) Prolonged Re-sponse to First‐Generation Tyrosine Kinase Inhibitor in a Metastatic Non‐Small Cell Lung Cancer Harbouring Complex G719X and S768I Mutations: A Case Report from Vietnam and Literature Review. Respirology Case Reports, 11, e01131. https://doi.org/10.1002/rcr2.1131
Lee, C., Milone, M. and Seetharamu, N. (2021) Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data. OncoTargets and Therapy, 14, 4579-4597. https://doi.org/10.2147/ott.s227032
Olsson, C.A., Moyer, J.D. and Laferte, R.O. (1971) Pulmonary Cancer Metastatic to the Kidney—A Common Renal Neoplasm. Journal of Urology, 105, 492-496. https://doi.org/10.1016/s0022-5347(17)61556-8
Scatena, C., Comin, C.E., Lapini, A. and Raspollini, M.R. (2013) Renal Metastasis from Pulmonary Adenocarcinoma: The Pathologist’s Approach to an Uncommon Finding Case Report and Review of the Literature. Applied Immunohistochemistry & Molecular Morphology, 21, 460-463. https://doi.org/10.1097/pai.0b013e31827101b1
Ichimatsu, K., et al. (1998) Meta-static Renal Tumor Originating from Lung Cancer: Report of Two Cases. Japanese Journal of Urological Surgery, 18, 1259-1262.
Honda, H., Coffman, C.E., Berbaum, K.S., Barloon, T.J. and Masuda, K. (1992) CT Analysis of Metastatic Neoplasms of the Kidney. Acta Radiologica, 33, 39-44. https://doi.org/10.1080/02841859209173124
Lorenzi, M., Ferro, A., Cecere, F., Scat-tolin, D., Del Conte, A., Follador, A., et al. (2021) First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. The Oncologist, 27, 87-e115. https://doi.org/10.1002/onco.13951
Watanabe, K., Yoh, K., Hosomi, Y., Usui, K., Naka, G., Kishi, K., et al. (2022) Efficacy and Safety of First-Line Osimertinib Treat-ment and Postprogression Patterns of Care in Patients with Epidermal Growth Factor Receptor Activating Mutation-Positive Advanced Non-Small Cell Lung Cancer (Reiwa Study): Study Protocol of a Multicentre, Real-World Observational Study. BMJ Open, 12, e046451. https://doi.org/10.1136/bmjopen-2020-046451
